The TCRA ILBOW Story

Here are a few ways to rewrite the text of the s tory to make it dramatically compelling, depending on the tone and medium you intend to target:

Spectacular Wall Street story (by John)
There is an opportunity for the most spectacular Wall Street story of the year to be written by an influential financial writer in The Wall Street Journal, New York Times, Financial Times, Fortune, Forbes or Bloomberg. (See below for list of writers)

The heart of the story is describing how a remarkable confluence of circumstances in the emerging **$293billion** clinical lab industry is conspiring with powerful PE firm Blackstone to enable the largest fastest most profitable LBO that Blackstone will ever do. But incredibly, on top of that, this TCRA LBO will create an instant endowment of **$30 billion** for nonprofit WIRhE that will enable WIRhE to eradicate Rh Hemolytic Disease from the whole world, preventing **160 thousand** babies from dying and **100 thousand** young children from cerebral palsy every year for **hundreds of years**.

The TCRA high finance deal with a heart is so astonishingly big, bold and new because it will generate **$1 trillion** of future free-cash-flow in **two months**. **$500 billion** of future cash flow securitized by **50%** of TCRA shares will go into a DAF to fund WIRhE and other philanthropies. **$400 billion** of future cash flow securitized by **40%** of TCRA shares will go to energize the **6 selected** Fortune 500 sized companies who will become the new 'founder' shareholders of TCRA. Almost magically, a small California startup with a formidable portfolio of US and international patents on DLA, the revolutionary new clinical lab automation system, will instantly become a major Fortune 500 sized company.

An intriguing part of the story is that John and friends-and-family will walk away with the American Dream: ownership of **$100 billion** of future free-cash-flow.

(AI written)
Option 1: High-Stakes Financial Drama (Wall Street Journal / Bloomberg Style)

In the shadowed corridors of elite private equity, a jaw-dropping financial maneuver is about to rewrite history. This is not merely a deal—it is the setup for the most sensational Wall Street saga of the decade. Deep within the emerging **$293 billion global clinical laboratory industry**, an extraordinary confluence of market forces is aligning with private equity juggernaut **Blackstone**. The target? Executing the largest, fastest, and most wildly lucrative Leveraged Buyout the financial world has ever witnessed.

But behind the mind-boggling balance sheets lies an unprecedented human crusade. In a single stroke, this buyout—known as the **TCRA ILBOW**—will mint an instant **$30 billion cash endowment** for the non-profit **WIRhE**, handing humanity the weapon it needs to permanently eradicate Rh Hemolytic Disease. Every single year, for centuries to come, this deal will snatch **160,000 newborns from the jaws of death** and shield **100,000 children from the tragedy of cerebral palsy**.

It is high finance engineered with a human heart—an audacious strategy poised to conjure **$1 trillion in future free-cash-flow** out of thin air in just two months:

$500 Billion for Humanity: Securitized by 50% of TCRA's equity, a half-trillion dollars will pour into a donor-advised fund to ignite global philanthropy forever.
$400 Billion for Industry Giants: 40% of the company will energize six hand-selected Fortune 500 titans, transforming them into foundational co-creators of a new industrial paradigm.
$100 Billion American Dream: Almost magically, a scrappy California startup wielding a ironclad portfolio of international patents for **Dark Lab Automation (DLA)** will explode into a titan—leaving its founder, Dr. John Gorman, and his early inner circle holding a staggering **$100 billion fortune**.

Wall Street has seen mega-deals before, but it has never seen a coup that conquers high finance while rescuing millions of unborn lives.

(AI written)
Option 2: Cinematic Thriller / Feature Lead (Fortune / Forbes Feature Style)
What if the biggest buyout in Wall Street history didn't just break financial records—what if it saved 160,000 babies a year?

It sounds like the plot of a Hollywood financial thriller: a 95-year-old medical pioneer, a obscure California startup, and a patented technology capable of taking over a **$293 billion healthcare sector**. Add **Blackstone** into the mix, and you have the recipe for an explosion that will send shockwaves through the global financial markets.

Welcome to the story of **TCRA**—a high-finance masterstroke that fuses cutthroat private equity with unmatched humanitarian urgency.

Within sixty days, TCRA's revolutionary **Dark Lab Automation (DLA)** patent portfolio is set to unlock **$1 trillion in guaranteed future cash flows**. But unlike any LBO before it, this deal allocates its spoils with breathtaking audacity:

- **A $30 Billion Miracle:** Instantly endowing the non-profit WIRhE to wipe Rh Hemolytic Disease off the face of the Earth—sparing **100,000 infants annually from lifelong disability** and saving **160,000 lives** every year in perpetuity.

- **$500 Billion in Philanthropic Firepower:** Anchored by 50% of TCRA's shares, half a trillion dollars will flow directly into a powerhouse philanthropic endowment.

- **A $400 Billion Industrial Alliance:** 40% of the entity will be handed to six elite Fortune 500 heavyweights, aligning the world's most powerful corporations behind a single, dominant lab automation standard.

- **The Ultimate $100 Billion Triumph:** In an astonishing victory for visionary persistence, founder Dr. John Gorman and his family-and-friends backers will secure a **$100 billion stake**, cementing the ultimate American Dream.

The stage is set. The numbers are staggering. The lives hanging in the balance are real. Wall Street is about to witness a miracle wrapped inside a multi-billion-dollar deal.

Key Enhancements Made:

- **Active, Cinematic Verbs:** Replaced passive phrasing with strong action words (*snatch, conjure, send shockwaves, align, explode*).

- **Clear Bullet Points:** Structured the complex cash-flow allocations ($500B / $400B / $100B) so journalists and readers can immediately digest the staggering numbers.

- **Heightened Stakes:** Emphasized the contrast between cold, hard Wall Street numbers ($1 Trillion, Blackstone LBO) and the emotional human reality (saving 160,000 babies annually).

Background (By John)
TCRA LLC is a small startup with key clinical lab automation patents owned by John's friends and family. They wish to immediately give away **90%** of TCRA shares. This new capital structure will convert TCRA instantly into a big, important new company with significant heft and **hundreds of billions** of US dollars in company valuation.

"In the TCRA high finance deal, Blackstone will make the **Big 6**, *Blackstone, Siemens, Roche, Abbott, Danaher, Amazon One Medical*, the new major shareholders of TCRA. This new TCRA capital structure will confer an immediate company valuation of **$300 billion** on TCRA. **Based on** the sheer power of TCRA's well-placed new team, its public intent to revolutionize the automation of the world's clinical labs, and its ability to generate **$1 trillion** in future free-cash-flow for TCRA shareholders from the world's clinical labs (**$100B** for Blackstone itself). Blackstone will immediately raise a **$30 billion** cash endowment for WIRhE at a TCRA company valuation of **$300 billion**, thereby funding the saving of the Rh babies **forever**."

TCRA is offering **10%** of TCRA to *Blackstone* if they will ILBOW TCRA and make TCRA as valuable as possible, i.e. **10%** of TCRA shares at no cost, **$100 billion** of royalties. TCRA will offer each of **Big 4**, *Siemens, Roche, Abbott and Hanover*, if they commit to join the LBO of TCRA i.e. **6%** of TCRA shares at no cost, **$60 billion** of royalties. And offer another **6%** to *Amazon One* if they commit to develop a DLA and compete in the clinical lab automation market with the **Big 4**. TCRA is putting **50%** of TCRA shares, i.e. **$500 billion** of royalties, in a DAF for WIRhE and other philanthropy.

Most notable dramatic financial stories like *The Big Short* are written after the event has happened. There is risk in writing about future speculative events no matter how exciting. Lets hope one of the writers below will take that risk, ameliorated yet by what a terrific story coup for them, and that their story will be the trigger that saves the Rh babies in the Global South.

The purpose of this document is to script an interesting story. With personalities. The target of the story are the billionaires in the Rh club list who are philanthropic and could readily become interested in saving the Rh babies and give us access to BX.

Right now, John is crying in the wilderness. His TCRA pitch is being censored by almost everyone who could carry it forward. It is the elephant in the room that nobody wants to talk about. Apparently inhibited by fear of being associated with a high finance deal so astonishingly big, bold and new. The actual risk people see in backing TCRA is hard to define. But the risk is clearly very real in their minds because their opportunity to save the Rh babies does not overcome their bystander effect i.e. themselves doing something for the Rh babies. WIRhE needs just one influential Wall Street mogul to take the risk and back TCRA. Others will then follow.

The story is also personal, about the end-of-life mission of Dr. John Gorman, 95-year-old inventor of RhoGAM, to resolve the Rh Hemolytic Disease (RDFN) crisis in the Global South. Half ot the Rh Negative mothers in the world are not being protected with anti-D. **160 thousand** Rh babies still die and **100 thousand** get cerebral palsy. John has come up with this *ingenious high finance deal with a heart* called TCRA that will quickly provide way more than adequate funds for WIRhE, the nonprofit dedicated to eradication of RDFN in the whole world.

One way to get this Wall Street mogul's attention is a story by an influential financial writer. So, the TCRA story is best written by one of the **most-influential** finance writers below who can be grouped by their focus: behavioral wealth and investing principles, traditional personal finance and debt management, or deep financial journalism. These writers have sold millions of books, shaped market behaviors, and redefined how everyday people view wealth, investing, and the global economy. [1, 2, 3, 4, 5] A story by one of them will get John's message to all the relevant people.

Behavioral Wealth & Investing Philosophy

Morgan Housel: Author of the massive global bestseller *The Psychology of Money*. He focuses heavily on the human, behavioral side of decision-making rather than formulas. [1, 2, 3, 4, 5]

Nassim Nicholas Taleb: Author of *The Black Swan* and the *Incerto* series. He is highly influential for his writing on risk engineering, probability, and market fragility. [1]

JL Collins: Author of *The Simple Path to Wealth*, the definitive text for the Financial Independence, Retire Early (FIRE) movement. He popularized ultra-simple, low-cost index fund investing. [1, 2, 3, 4, 5]

Jason Zweig: Columnist for The Wall Street Journal and editor of Benjamin Graham's definitive text *The Intelligent Investor*. He is widely cited for his work blending neuroscience with investing habits. [1]

Personal Finance & Wealth Building

Ramit Sethi: Author of the bestseller *I Will Teach You To Be Rich*. He focuses on automated investing, negotiation, and spending guilt-free on things you love. [1, 2]

Dave Ramsey: Author of *The Total Money Makeover* and architect of the "Baby Steps" framework. His strict anti-debt philosophy has helped millions clear personal liabilities. [1, 2, 3, 4, 5]

Suze Orman: Author of multiple number-one bestsellers like *The Money Class* and *The 9 Steps to Financial Freedom*. She is one of the most recognizable voices in traditional American personal finance. [1, 2, 3, 4, 5]

Robert Kiyosaki: Author of *Rich Dad Poor Dad*. Though controversial for his modern takes, his core early text fundamentally changed how people view assets versus liabilities. [1, 2]

Financial Journalism & Investigative Reportage

Michael Lewis: Author of *The Big Short*, *Flash Boys*, and *Liar's Poker*. He is arguably the most successful narrative non-fiction writer covering Wall Street corruption and market mechanics.

Andrew Ross Sorkin: Founder of *DealBook* for The New York Times and author of *Too Big to Fail*. He is one of the ultimate insiders for corporate mergers and Wall Street crises.

Gillian Tett: Writer and editor for the *Financial Times*. She famously predicted the 2008 financial crash by tracking complex credit-derivatives markets before anyone else.

Ron Lieber: The "Your Money" columnist for The New York Times. He focuses extensively on consumer protection, college financing, and family wealth mechanics. [1, 2, 3, 4, 5]

Here's a **sample script** for the story told through the lens of Blackstone. Can this prominent writer or CNBC host get an interview with Jon Gray or Steven Schwartzman at Blackstone or Tony James?

Jon Gray, CEO of Blackstone (BX), has become aware of TCRA LLC's potential as an LBO. His immediate reaction is excitement at the boldness of this extraordinary TCRA high finance deal. His first impressions are that an LBO of TCRA will be big, the largest that Blackstone will ever make. He particularly likes its ingenuity, based on a new idea, never been done before. **The most accelerated LBO ever!**

He brings the TCRA company before Blackstone's **Tactical Opportunities** investment committee that he is a member of. Their response is the same excitement, and they rapidly organize **a deal team** to double check the details of the TCRA opportunity. The deal team quickly discovers that under an ingenious LBO plan devised by TCRA, TCRA annual revenues will be a very sure **$40 billion**, EBITDA **95%,** starting in **2 years** and steadily increasing for another **15 years**. The ability for Blackstone to create such **amazing gain of value** in a company so easily in such a short time grabs their interest.

They see clearly that the opportunity for BX to bring about a **huge gain of value** for TCRA arises from a unique confluence of factors that have occurred in the enormous clinical lab industry.

What the BX deal team finds:

- The first and key factor for an LBO of TCRA by BX is that in the last **60 years** diagnostics have become sine qua non essential for medical care. Clinical lab test results drive **70%** of actionable decisions in the care of patients. Cases cannot be managed today without lab test data.

- Second, the market for lab test data globally is **$293 billion** annually, almost exactly on par with the US domestic airlines' revenues.

- **90 percent** of clinical lab tests are now run on automated clinical analyzers. **66 percent** of the world's lab test volume on highly automated TLA analyzers manufactured by an entrenched oligopoly of **4** powerful Fortune 500 sized companies: *Siemens, Roche, Abbott and Hanover*, the Big **4**.

- This clinical lab automaton oligopoly took the wrong direction in clinical lab automation **30 years** ago, developing so-called **TLA**, total lab automation. After **30 years** TLA automation **has reached a dead end**, leaving clinical labs just **50%** automated, half the labor still manual. Further improvement in the level of automation is impossible with the TLA approach.

- There is a relatively straightforward way to automate the manual work still done under TLA lab automation: **use DLA**, a different approach that should have been taken **30 years** ago.

Commented [JG1]: With TLA clinical lab automation only samples are transported on lengthy tracks out to automated analytic modules embedded in large expensive analyzers. All other supplies needed to run the tests have to be carried out to the analyzer and installed by a technician by hand. TLA clinical labs are only 50% automated. TLA is at a dead end after 30 years and has to be replaced. In future clinical lab automation all other supplies will be autonomously transported out to available standalone automated analytic modules. TCRA has patented thus principle.

- TCRA owns a formidable portfolio of DLA patents, allowed and pending, in the United States, China, Europe, Korea, Canada, Japan, Australia, and Hong Kong.

Commented [JG2]: I have spend over$300,000 on the TCRA patents. It will be worthwhile for the new TCRA to make further major investments, develop licensing contracts for manufacturers and clinical labs. Plan for effective litigation if becomes necessary.

- If the Big 4 oligopoly uses TCRA intellectual property in a new DLA line of automated analyzers, global clinical labs will pay **$1 trillion** in royalties to TCRA, on the **$8 trillion** of revenues those DLA analyzers will earn over the life of the TCRA patents. TCRA shares will become very valuable once Big 4 declare their intent to go ahead with DLA.

- The deal team understands that the company value of TCRA depends almost entirely on the prestige, track record, commercial and legal strength of the parties doing the LBO of TCRA. (vs. the SpaceX IPO) TCRA will invite a dream team of 'new startup founders' with absolute credibility to launch a new TCRA startup with great verve.

- After preliminary investigations the BX deal team reports back to their investment committee strongly that Bx's role is to recruit and manage this powerful LBO sponsor group, not do the LBO by themselves.

- The BX investment committee realizes that this unique confluence of circumstances in the clinical lab industry is **amazing serendipity**; that they should not let their part in the deal slip for lack of imagination; rejoicing that BX fortunately is at the right place at the right time with the right resources. Immediate ownership of **$60 billion** cash flow with no investment is a very worthwhile return for BX."